To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH).
Methods:
A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day. Patients received 3 consecutive monthly IV injections of ranibizumab starting from 15 days after PD. During the follow-ups, additional ranibizumab treatment was performed if persistent macular or recurrent subretinal or intraretinal fluid hemorrhage was observed.
Results:
The mean central retinal thickness was 489 ± 92 μm (311-621 μm) at the time of diagnosis, 324 ± 56 μm (209-409 μm) at the first month, 262 ± 48 μm (197-364 μm) at 3 months, 248 ± 40 μm (190-334 μm) at 6 months, and 253 ± 41 μm (192-356 μm) at the last control (p<0.01). The mean best-corrected visual acuity was 2.08 ± 0.79 logMAR (0.7-3.0 logMAR) at baseline, 1.41 ± 0.70 logMAR (0.56-2.50 logMAR) at the first month, 1.21 ± 0.66 logMAR (0.3-2.0 logMAR) at 3 months, 1.14 ± 0.77 logMAR (0.2-2.50 logMAR) at 6 months, and 1.09 ± 0.73 logMAR (0.3-2.50 logMAR) at the last follow-up (p<0.01).
Conclusions:
Sequential IV tPA, PD, and IV anti-VEGF treatments for SMH in patients with nAMD is effective. However, further studies are needed to establish the best treatment algorithm for SMH in patients with nAMD.
AveryRLFekratSHawkinsBSBresslerNM.Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16(3):183-189.
2.
BennettSRFolkJCBlodiCFKlugmanM.Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990;109(1):33-37.
3.
GlattHMachemerR.Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94(6):762-773.
4.
TothCAMorseLSHjelmelandLMLandersMBIII. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109(5):723-729.
5.
HassanASJohnsonMWSchneidermanTEet al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106(10):1900-1906, discussion 1906-1907.
6.
SinghPSinghRKishoreKSVigVKSinghRSinghB.Intravitreal tissue plasminogen activator in submacular haemorrhage. Indian J Ophthalmol. 1999;47(4):254-255.
7.
OhjiMSaitoYHayashiALewisJMTanoY.Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998;116(10):1326-1332.
8.
MaheshGGiridharASaikumarSJEliasA.Intravitreal gas for submacular haemorrhage. Indian J Ophthalmol. 2003;51(4):349-350.
9.
ChawlaSMisraVKhemchandaniM.Pneumatic displacement and intravitreal bevacizumab: a new approach for management of submacular hemorrhage in choroidal neovascular membrane. Indian J Ophthalmol. 2009;57(2):155-157.
10.
AgarwalMChaudharySPNarulaRRajpalS.Pneumatic displacement and intravitreal bevacizumab for management of submacular hemorrhage in choroidal neovascular membrane. Indian J Ophthalmol. 2010;58(2):170-171.
11.
ThompsonJTSjaardaRN.Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc. 2005;103:98-107, discussion 107.
12.
WadeECFlynnHWJrOlsenKRBlumenkranzMSNicholsonDH.Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol. 1990;108(7):973-978.
13.
HaupertCLMcCuenBWIIJaffeGJet al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131(2):208-215.
14.
ShahSPHubschmanJPGonzalesCRSchwartzSD.Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2009;40(3):308-315.
15.
TreumerFRoiderJHillenkampJ.Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96(5):708-713.
16.
GehrsKMHeriotWJde JuanEJr.Transmission electron microscopic study of a subretinal choroidal neovascular membrane due to age-related macular degeneration. Arch Ophthalmol. 1992;110(6):833-837.
17.
HesseLSchmidtJKrollP.Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237(4):273-277.
18.
LeeJPParkJSKwonOWYouYSKimSH.Management of acute submacular hemorrhage with intravitreal injection of tenecteplase, anti-vascular endothelial growth factor and gas. Korean J Ophthalmol. 2016;30(3):192-197. Published online May18, 2016.
19.
HöhnFMirshahiAHattenbachLO.[Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration]. Ophthalmologe. 2010;107(4):328-332.
20.
MeyerCHSchollHPEterNHelbHMHolzFG.Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008;86(5):490-494.
21.
SacuSStifterEVécsei-MarlovitsPVet al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond). 2009;23(6):1404-1410.
22.
GuthoffRGuthoffTMeigenTGoebelW.Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. 2011;31(1):36-40.
23.
KlettnerAGrotelüschenSTreumerFRoiderJHillenkampJ.Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. 2015;99(6):864-869.
24.
KlettnerAPulsSTreumerFRoiderJHillenkampJ.Compatibility of recombinant tissue plasminogen activator and bevacizumab co-applied for neovascular age-related macular degeneration with submacular hemorrhage. Arch Ophthalmol. 2012;130(7):875-881.
25.
Stanescu-SegallDBaltaFJacksonTL.Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Surv Ophthalmol. 2016;61(1):18-32.
26.
MayerWJHakimIHaritoglouCet al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol. 2013;91(3):274-278.
27.
PapavasileiouESteelDHLiazosEMcHughDJacksonTL.Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration. Retina. 2013;33(4):846-853.
28.
OshimaYOhjiMTanoY.Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage. Br J Ophthalmol. 2007;91(2):193-198.
29.
IsizakiEMorishitaSSatoTet al. Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear. Int Ophthalmol. 2016;36(2):199-206.
30.
LiuHZhangLLiXWuM.23-Gauge vitrectomy with external drainage therapy as a novel procedure to displace massive submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Medicine. 2016;95:(32):e4192.
